Artiva Biotherapeutics, an oncology company specializing in primary allogeneic natural killer (NK) cell therapies to treat cancer, announced on Aug. 12, 2021 an expansion of its US presence with a new R&D and GMP manufacturing facility in San Diego, Calif., for cell therapies.
New facility at the existing facility in Milford, MA, USA will significantly expand cGMP manufacturing capabilities and accelerate the clinical and commercial supply of vital biopharmaceuticals
Ecolab Inc., the global leader in water, hygiene and infection prevention solutions and services, is opening the Ecolab Healthcare Advanced Design Center in Eagan, Minn.
Bacterial spores from Earth still manage to find their way into outer space aboard spacecraft. Fox and his team are examining how and why some spores elude decontamination. Their research is published in “BMC Microbiology.”
In our design, self-assembly of MOF nanoparticles and encapsulation of proteins are achieved simultaneously through a one-pot approach in aqueous environment. The enriched metal affinity sites on MOF surfaces act like the buttonhook, so the extracellular vesicle membrane can be easily buckled on the MOF nanoparticles.
Researchers uncovered a heterogeneous catalysis strategy that deliberately targets post-C-C coupling reaction intermediates during CO2 electrochemical reduction reaction. It opens avenues to the design of efficient catalysts that selectively produce higher-carbon liquid alcohols.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has signed a definitive asset purchase agreement to acquire CTP-656 from Concert Pharmaceuticals (Nasdaq: CNCE). CTP-656 is an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that has the potential to be used as part of future once-daily combination regimens of CFTR modulators that treat the underlying cause of cystic fibrosis (CF). As part of the agreement, Vertex will pay Concert $160 million in cash for all worldwide development and commercialization rights to CTP-656.
Researchers at Oregon State University and Oregon Health & Science University are working on a treatment that holds great promise for improving the lives of cystic fibrosis patients. Cystic fibrosis is a progressive genetic disorder that results in persistent lung infection and afflicts 30,000 people in the U.S., with about 1,000 new cases diagnosed every year.
The last 10 years have seen a surge in the use of tiny substances called nanomaterials in agrochemicals like pesticides and fungicides. The idea is to provide more disease protection and better yields for crops, while decreasing the amount of toxins sprayed on agricultural fields.
Research team discovers drug compound that stops cancer cells from spreading Via a mouse model, OHSU...
Minakem’s HPAPI production will be carried out with an Occupational Exposure Limit (OEL) below 0,1μg/m3/8h. This emphasis on Environment, Health and Safety (EHS) reflects Minakem’s more than 20 years’ experience in continuously monitoring and controlling hazardous working environments, marking its leadership in this area.
Shire plc, the global biotechnology leader in rare diseases, announced today that the United States Food and Drug Administration (FDA) has approved the company’s first submission for its new plasma manufacturing facility near Covington, Georgia for the production of GAMMAGARD LIQUID® [Immune Globulin Infusion (Human)] 10% Solution, a replacement therapy for primary humoral immunodeficiency (PI).